Stocks Health care TGTX
NASDAQ · Health careTG Therapeutics, Inc. (TGTX)
TG Therapeutics, Inc. brought in $799.5M of revenue over the twelve months to June 30, 2026, up 76.1% from a year earlier. Net income was $441.5M, a net margin of 55.2%. In fiscal 2025 capital spending exceeded operating cash flow by $25M. At June 30, 2026 it held $482.6M in cash against $745.4M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What TG Therapeutics, Inc. does
TG Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TGTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $616.3M | $447.2M | $2.77 | -$25M |
| 2024 | $329M | $23.4M | $0.15 | -$40.6M |
| 2023 | $233.7M | $12.7M | $0.09 | -$31.4M |
| 2022 | $2.8M | -$223.8M | -$1.65 | -$176.2M |
| 2021 | $6.7M | -$348.1M | -$2.97 | -$296M |
| 2020 | $152K | -$279.4M | -$2.73 | -$214.9M |
Latest SEC filings
What TG Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 3, 2026
- June 12, 2026
- June 3, 2026Other event 8-K
- May 27, 2026Other event 8-K
- May 6, 2026Quarterly report 10-Q · period to March 31, 2026
- May 6, 2026
- April 30, 2026Proxy statement DEF 14A
- April 29, 2026Passive stake (5% or more) SCHEDULE 13G
- March 27, 2026Passive stake changed SCHEDULE 13G/A
Questions about TGTX
What does TG Therapeutics, Inc. do?
TG Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TGTX.
Is TG Therapeutics, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $441.5M on revenue of $799.5M, a net margin of 55.2%.
How much revenue does TG Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 TG Therapeutics, Inc. reported revenue of $799.5M. That is 76.1% more than a year earlier.
When did TG Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 14, 2026.
Similar companies
Follow TGTX
Get an email when TG Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow TGTX: get an email when it filesWhere the numbers come from
Financial figures are the values TG Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.